Favorable

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- VionPharmaceuticals, Inc. announced that it presented clinical data ina poster session at the 12th Congress of the European HematologyAssociation (EHA) Meeting in Vienna, Austria on its lead anticanceragent Cloretazine(R) (VNP40101M) as a single agent in amulti-center international Phase II clinical trial in a subset ofelderly pat...

Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- According tostudy results presented today at the 2007 American PsychiatricAssociation annual meeting, iloperidone, an investigationalatypical antipsychotic, was shown to have a favorable akathisiaprofile. Akathisia -- a debilitating sensation of restlessness thatmanifests as an inability to sit still -- is a frequent side effectof antipsy...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

Six-Month Data Show Bifeprunox Maintained StabilitySignificantly Longer than Placebo and had a Favorable Weight andLipid Profile Comparable with Placebo MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - SolvayPharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth(NYSE:WYE), and Lundbeck A/S presented clinical study results onbifeprunox, an investigational treatment for...

Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo

COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , SolvayPharmaceuticals, Inc. and Lundbeck A/S presented clinical studyresults on bifeprunox at an international medical congress thisweek. Safety analyses suggest bifeprunox, an investigationaltreatment for adult patients diagnosed with schizophrenia, wasassociated with a favorable weig...